

ANNUAL REPORT 2013

Gilead

To Our Stockholders, Employees and Friends:  
In 2013, Gilead made major advances across our areas of therapeutic focus, significantly expanded the company's global reach, delivered medicines to a record number of patients and announced the strongest revenues in the company's history.



Left to right: Gregg H. Alton, Executive Vice President, Corporate and Medical Affairs; John McHutchison, MD, Executive Vice President, Clinical Research; Robin L. Washington, Executive Vice President and Chief Financial Officer; John F. Milligan, PhD, President and Chief Operating Officer; John C. Martin, PhD, Chairman and Chief Executive Officer; Norbert W. Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer; Katie L. Watson, Senior Vice President, Human Resources; Paul R. Carter, Executive Vice President, Commercial Operations.

The approval and introduction of Sovaldi® as a treatment for chronic hepatitis C virus (HCV) infection stands out among Gilead's 2013 accomplishments. For millions of people living with HCV, Sovaldi-based therapy may offer a cure with a significantly shorter and less burdensome course of treatment. Gilead also advanced new HIV products and research during the past year and made significant progress in oncology, the company's newest therapeutic area of focus. Fueled by strong commercial performance, Gilead's financial position is stronger than ever, with record total revenues in 2013 of \$11.2 billion.

Each of the milestones and accomplishments of the past year exemplify Gilead's mission of developing and delivering medicines that redefine how serious diseases are treated. Our accomplishments also exemplify the dedication of Gilead's 6,000 employees, who collaborate with the medical community, partners and each other to understand and to pursue what's in the best interest of patients.

#### A New Era in Hepatitis C Treatment, Continued Focus on Liver Diseases

On December 6, Sovaldi, a once-daily nucleotide analog polymerase inhibitor for the treatment of chronic HCV infection, was approved by the U.S. Food and Drug Administration (FDA) as a component of a combination antiviral treatment regimen. This milestone is the culmination of many years of work—developing the molecule, designing clinical trials to best define its use across various genotypes and patient populations, and ensuring involvement of the medical community, which has long awaited a new treatment. In addition, Gilead worked quickly to build an experienced commercial and medical affairs organization prepared to support the introduction of Sovaldi around the world.

Sovaldi's efficacy has been established in patients with HCV genotypes 1, 2, 3 or 4 infection. In certain Phase 3 studies in combination with other medicines, Sovaldi achieved cure rates as high as 90 percent, while shortening the duration of therapy from 24–48 weeks to 12 weeks in some patients and altogether eliminating the need for debilitating interferon injections in other patients.

The product was approved in Canada in mid-December and regulatory filings in Turkey, Switzerland, Australia and New Zealand set the stage for additional approvals in 2014. In the European Union, it received a positive opinion from the Committee for Medicinal Products for Human Use in late November and full European Commission approval in January 2014. In Japan, an agreement with the Japanese regulatory agency (Pharmaceuticals and Medical Devices Agency) was established, and Phase 3 clinical trials of sofosbuvir in combination with other medicines were initiated and fully enrolled, with the goal of submitting a regulatory filing in the second half of 2014. Gilead's operations in Japan were formally established in late 2013, and the commercial organization will be fully built and staffed over the course of 2014.

Sovaldi has the potential to become the cornerstone of interferon-free, all-oral treatment regimens that achieve

higher cure rates more rapidly and with fewer side effects. On December 18, topline results were announced from three Phase 3 studies demonstrating that a single tablet regimen of sofosbuvir and the investigational NS5A inhibitor, ledipasvir, can provide high cure rates without the need for interferon or ribavirin in the treatment of patients with genotype 1 infection, which accounts for a majority of HCV cases in North America and Europe. The U.S. regulatory filing for this fixed-dose combination was completed in February 2014. Also underway is the clinical development of the pan-genotypic NS5A inhibitor, GS-5816, which may have the potential to simplify therapy for all HCV patients, irrespective of viral genotype.

In the area of chronic hepatitis B, Gilead initiated a Phase 3 program for tenofovir alafenamide (TAF), a novel, low-dose prodrug of tenofovir that has the potential to optimize clinical efficacy, safety and tolerability relative to existing chronic hepatitis B virus (HBV) therapies. For most patients with chronic hepatitis B, life-long antiviral therapy is required. Curing HBV infection is the ultimate goal and Gilead is pursuing novel therapies and approaches such as oral medicines and therapeutic vaccines that may provide finite treatment for patients.

#### Innovating in HIV Medicine

Gilead continues its efforts to improve treatment for HIV and expanding access to therapy for patients around the world. Stribild® became the leading prescribed regimen for treatment-naïve HIV patients in the United States, received European Commission approval in May and was subsequently launched in the United Kingdom, Austria, Germany, Luxembourg, Ireland, Spain, Poland, Switzerland, the Netherlands and all five Nordic countries. Uptake of this product increased significantly throughout the year in the United States and Europe. Data characterizing the efficacy and safety of Stribild over three years were presented in October at the annual conference of the European AIDS Clinical Society. Gilead's second single tablet regimen for HIV, Complera®, received a prescribing label expansion in the United States to include suppressed patients switching from a stable antiretroviral treatment regimen. In Europe, where it is marketed as Eviplera®, the product received a similar expanded indication.

Tybost®, a boosting agent for certain protease inhibitor-based regimens, and Vitekta®, an integrase inhibitor, were approved in the European Union and Canada in the second half of 2013. Following receipt of a Complete Response Letter from FDA in April 2013, Gilead is working to resubmit applications for both of these products in the United States. In January 2013, a large-scale Phase 3 clinical program was initiated for Gilead's newest single tablet regimen of TAF combined with elvitegravir, cobicistat and emtricitabine. Phase 2 data for the TAF-based single tablet regimen presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy in September showed that it was similar to Stribild in efficacy, with what appears to be a more favorable safety profile in terms of renal and bone indicators. These data support the potential of TAF to become a key component of Gilead's next-generation single tablet regimens. Initial results from the large-scale Phase 3 program are anticipated in early 2015.

## Significant Advances in Oncology

In late 2013, marketing applications were submitted in the United States and the European Union for Gilead's lead oncology treatment, idelalisib, a first-in-class PI3K delta inhibitor, for patients with indolent non-Hodgkin's lymphoma (iNHL) or chronic lymphocytic leukemia (CLL) who do not respond to or who can't tolerate existing treatments. The filings were based on encouraging clinical study results, including results of a Phase 3 CLL study that was stopped early due to a statistically significant efficacy advantage in the idelalisib arm. The product was awarded "breakthrough designation" by the FDA for relapsed CLL, and review is expected to be completed by early August 2014. Studies are ongoing to further characterize idelalisib's clinical profile. iNHL and CLL are cancers of the lymphatic system and advancing new treatment options for these patients is critical.

A pivotal Phase 3 clinical trial was recently initiated for the novel JAK inhibitor momelotinib for the treatment of myelofibrosis, a life-threatening bone marrow disorder. Momelotinib came to Gilead with the acquisition of YM BioSciences, Inc., which was completed in February 2013.

## Progress in Cardiovascular and Respiratory Disease

Gilead's commercial products for cardiovascular and respiratory diseases together exceeded \$1 billion in annual revenues for the first time in 2013. In the area of cardiovascular disease, data from a Phase 4 trial of Ranexa® showed a reduced incidence of chest pain among chronic angina patients with type 2 diabetes. Phase 3 studies of Ranexa in type 2 diabetes are ongoing, and data should become available in 2014. In August 2013, Letairis®, an endothelin receptor antagonist (ERA) medicine for the treatment of pulmonary arterial hypertension (PAH), received a favorable change to the product's Risk Evaluation and Mitigation Strategy (REMS). As a consequence of this new modification, only females of reproductive potential will have to enroll into and be monitored regularly through the Letairis REMS program, which greatly lessens the burden on prescribers and the majority of patients. Letairis is now the most frequently prescribed ERA therapy for newly diagnosed PAH patients.

During 2013, Cayston®, an inhaled antibiotic used to improve respiratory symptoms in people with cystic fibrosis who have *Pseudomonas aeruginosa*, was added to pulmonary treatment guidelines. The product is now recommended for chronic use in people living with the disease. Also in the area of respiratory disease, simtuzumab continues to progress in Phase 2 clinical studies for idiopathic pulmonary fibrosis (IPF). IPF is a chronic disease characterized by a progressive scarring of the lungs. Simtuzumab is also being studied in various Phase 2 studies for liver fibrosis and solid tumors. A potent and well tolerated inhibitor of respiratory syncytial virus (RSV) called GS-5806 is being studied in Phase 2 trials. RSV is the most common cause of bronchiolitis and pneumonia in children under 1 year of age in the United States.

## Expanding Access for Patients

Across therapeutic areas, Gilead works to ensure access to the company's medicines, regardless of patients' ability to pay for healthcare or where they live in the world. 2013 marked the 10th anniversary of Gilead's global HIV treatment access program. Today, the company's antiretrovirals reach more than 4.7 million people in developing countries, representing nearly 50 percent of all patients on antiretroviral therapy in resource-limited settings. This accomplishment is the result of the voluntary licensing partnerships with multiple generic drug manufacturers in India and South Africa that have helped to expand supply and reduce the cost of therapy. In the area of chronic hepatitis C, Gilead is working to register Sovaldi in a number of developing countries. Local clinical trials in certain countries—including Egypt, which has a high prevalence of the disease and a well-established healthcare infrastructure—also are underway.

In the United States, comprehensive patient assistance programs provide Gilead medicines for uninsured individuals, as well as for those who cannot afford health insurance co-pays.

## Addressing Future Patient Needs

To support the progress Gilead made in drug development and commercialization in 2013, Gilead's international presence expanded with measured growth in Asia-Pacific, Latin America and Eastern Europe, through the establishment of new affiliate operations in Japan, Brazil, Russia and the Czech Republic. Gilead's growing global operations will allow the company to reach more patients than ever before.

I would like to thank our shareholders for their ongoing support, Board of Directors for its continued guidance and our employees, partners and stakeholders for their contributions.

All of us at Gilead look forward to further exciting developments in 2014, as we work to provide innovative therapeutic options for people with life-threatening diseases around the world.



John C. Martin, PhD  
Chairman and Chief Executive Officer

### Forward-Looking Statement


This Annual Report includes forward-looking statements regarding our clinical studies and product candidates, including the anticipated timing and achievement of certain development milestones, regulatory filings and product launches. Such statements are predictions and involve risks and uncertainties such that actual results may differ materially. Please refer to Gilead's Annual Report on Form 10-K for the year ended December 31, 2013 attached to this report for the risks and uncertainties affecting Gilead's business. Gilead disclaims any obligation to update any forward-looking statements in this report.

# FINANCIAL HIGHLIGHTS


PRODUCT SALES  
(\$ IN MILLIONS)




TOTAL REVENUES  
(\$ IN MILLIONS)



EARNINGS PER SHARE



CASH AND CASH EQUIVALENTS  
(\$ IN MILLIONS)



\* Non-GAAP amounts may not sum due to rounding.

• Non-GAAP diluted earnings per share for 2011 exclude after-tax acquisition-related expenses of \$0.05 and stock-based compensation expenses of \$0.09.

• Non-GAAP diluted earnings per share for 2012 exclude after-tax acquisition-related expenses of \$0.08, restructuring expenses of \$0.01 and stock-based compensation expenses of \$0.22.

• Non-GAAP diluted earnings per share for 2013 exclude after-tax acquisition-related expenses of \$0.11 and stock-based compensation expenses of \$0.11.

\* During 2011, Gilead issued \$4.66 billion in senior unsecured notes, of which \$3.67 billion was raised in December 2011 to partially fund the Pharmasset, Inc. acquisition. The acquisition was completed in January 2012.

# Marketed Products

## HIV/AIDS



**ATRIPLA®**  
EFAVIRENZ 600 MG/EMTRICITABINE  
200 MG/TENOFOVIR DISOPROXIL  
FUMARATE 300 MG  
HIV/AIDS  
BRISTOL-MYERS SQUIBB COMPANY  
(U.S., WESTERN EUROPE, CANADA)  
MERCK & CO., INC. (REST OF WORLD)



**COMPLERA®**  
EMTRICITABINE 200 MG/RILPIVIRINE 25 MG/  
TENOFOVIR DISOPROXIL FUMARATE 300 MG  
HIV/AIDS  
JANSSEN R&D IRELAND (SELECT MARKETS)  
MARKETED AS EVIPLERA® IN EUROPE



**EMTRIVA®**  
EMTRICITABINE 200 MG  
HIV/AIDS  
JAPAN TOBACCO INC. (JAPAN)



**STRIBILD®**  
ELVITEGRAVIR 150MG/COBICISTAT 150MG/  
EMTRICITABINE 200MG/TENOFOVIR  
DISOPROXIL FUMARATE 300MG  
HIV/AIDS  
JAPAN TOBACCO INC. (JAPAN)



**TRUVADA®**  
EMTRICITABINE 200 MG/TENOFOVIR DISOPROXIL  
FUMARATE 300 MG  
HIV/AIDS  
JAPAN TOBACCO INC. (JAPAN)



**\*TYBOST®**  
COBICISTAT 150 MG  
HIV/AIDS



**VIREAD®**  
TENOFOVIR DISOPROXIL FUMARATE 300 MG  
HIV/AIDS  
JAPAN TOBACCO INC. (JAPAN)

## HIV/AIDS (CON'T)



**\*VITEKTA®**  
ELVITEGRAVIR 85 MG AND 150 MG  
HIV/AIDS

## LIVER DISEASES



**HEPSERA®**  
ADEFOVIR DIPIVOXIL 10 MG  
CHRONIC HEPATITIS B  
GLAXOSMITHKLINE INC.  
(CHINA, JAPAN, SAUDI ARABIA)



**SOVALDI®**  
SOFOSBUVIR 400 MG  
CHRONIC HEPATITIS C



**VIREAD®**  
TENOFOVIR DISOPROXIL FUMARATE 300 MG  
CHRONIC HEPATITIS B  
GLAXOSMITHKLINE INC. (CHINA)

## RESPIRATORY



**CAYSTON®**  
AZTREONAM FOR INHALATION SOLUTION  
75 MG/VIAL  
CYSTIC FIBROSIS, *PSEUDOMONAS AERUGINOSA*



**TAMIFLU®**  
OSELTAMIVIR PHOSPHATE 75 MG  
INFLUENZA A & B  
F. HOFFMANN-LA ROCHE LTD  
(WORLDWIDE)

## CARDIOVASCULAR



**LETAIRIS®**  
AMBRISENTAN 5 MG AND 10 MG  
PULMONARY ARTERIAL HYPERTENSION  
(WHO GROUP 1)  
GLAXOSMITHKLINE INC. (OUTSIDE OF THE U.S.)  
MARKETED AS VOLIBRIS® OUTSIDE OF THE U.S.



**LEXISCAN®**  
REGADENOSON INJECTION 0.4 MG  
CORONARY VASODILATION  
ASTELLAS PHARMA INC. (U.S., CANADA)  
RAPIDSCAN (EUROPE AND SELECT OTHER  
MARKETS)



**RANEXA®**  
RANOLAZINE 500 MG AND 1000 MG  
CHRONIC ANGINA  
MENARINI GROUP (EUROPE AND SELECT  
OTHER MARKETS)

## OTHER



**AMBISOME®**  
AMPHOTERICIN B LIPOSOME FOR INJECTION  
50 MG/VIAL  
SEVERE FUNGAL INFECTIONS  
ASTELLAS PHARMA INC. (U.S., CANADA)  
DAINIPPON SUMITOMO PHARMA CO., LTD.  
(JAPAN)



**MACUGEN®**  
PEGAPTANIB SODIUM INJECTION 0.3 MG  
NEOVASCULAR (WET) AGE-RELATED  
MACULAR DEGENERATION  
EYETECH, INC. (U.S.)  
PFIZER INC. (OUTSIDE U.S.)



**VISTIDE®**  
CIDOFOVIR INJECTION 375 MG/VIAL  
CMV RETINITIS IN PATIENTS WITH AIDS

# Pipeline

## HIV/AIDS

EU APPROVAL AS TYBOST<sup>®</sup>; U.S. REGULATORY SUBMISSION  
COBICISTAT (PHARMACOKINETIC ENHANCER)  
POTENTIAL INDICATION: HIV/AIDS

EU APPROVAL AS VITEKTA<sup>®</sup>; U.S. REGULATORY SUBMISSION  
ELVITEGRAVIR (INTEGRASE INHIBITOR)  
POTENTIAL INDICATION: HIV/AIDS

PHASE 3  
SINGLE TABLET REGIMEN OF ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/  
TENOFVIR ALAFENAMIDE  
POTENTIAL INDICATION: HIV/AIDS

PHASE 2  
SINGLE TABLET REGIMEN OF DARUNAVIR/COBICISTAT/EMTRICITABINE/  
TENOFVIR ALAFENAMIDE  
POTENTIAL INDICATION: HIV/AIDS

## LIVER DISEASES

CHRONIC HEPATITIS C  
U.S. REGULATORY SUBMISSION  
FIXED-DOSE COMBINATION OF LEDIPASVIR AND SOFOSBUVIR  
(NS5A INHIBITOR/NUCLEOTIDE NS5B INHIBITOR)  
POTENTIAL INDICATION: CHRONIC HCV INFECTION

PHASE 2  
FIXED-DOSE COMBINATION OF SOFOSBUVIR AND GS-5816  
(PAN-GENOTYPIC NS5B/NS5A INHIBITORS)  
POTENTIAL INDICATION: CHRONIC HCV INFECTION

GS-9451 (NS3 PROTEASE INHIBITOR)  
POTENTIAL INDICATION: CHRONIC HCV INFECTION

GS-9669 (NON-NUCLEOSIDE NS5B SITE 2 POLYMERASE INHIBITOR)  
POTENTIAL INDICATION: CHRONIC HCV INFECTION

PHASE 1  
GS-9620 (TLR-7 AGONIST)  
POTENTIAL INDICATION: CHRONIC HCV INFECTION

CHRONIC HEPATITIS B  
PHASE 3  
TENOFVIR ALAFENAMIDE (NUCLEOTIDE REVERSE TRANSCRIPTASE  
INHIBITOR)  
POTENTIAL INDICATION: CHRONIC HBV INFECTION

PHASE 2  
GS-4774 (TARMOGEN T CELL IMMUNITY STIMULATOR)  
POTENTIAL INDICATION: CHRONIC HBV INFECTION

PHASE 1  
GS-9620 (TLR-7 AGONIST)  
POTENTIAL INDICATION: CHRONIC HBV INFECTION

OTHER  
PHASE 2  
SIMTUZUMAB (MONOCLONAL ANTIBODY)  
POTENTIAL INDICATION: LIVER FIBROSIS

PHASE 1  
GS-5745 (MMP9 MAB INHIBITOR)  
POTENTIAL INDICATION: ULCERATIVE COLITIS

## ONCOLOGY/INFLAMMATION

U.S. AND EU REGULATORY SUBMISSIONS  
IDELALISIB (PI3K DELTA INHIBITOR)  
POTENTIAL INDICATION: INDOLENT NON-HODGKIN'S LYMPHOMA

IDELALISIB (PI3K DELTA INHIBITOR)  
POTENTIAL INDICATION: CHRONIC LYMPHOCYTIC LEUKEMIA

PHASE 3  
MOMELOTINIB (JAK INHIBITOR)  
POTENTIAL INDICATION: MYELOFIBROSIS

PHASE 2  
SIMTUZUMAB (MONOCLONAL ANTIBODY)  
POTENTIAL INDICATION: PANCREATIC CANCER

SIMTUZUMAB (MONOCLONAL ANTIBODY)  
POTENTIAL INDICATION: MYELOFIBROSIS

SIMTUZUMAB (MONOCLONAL ANTIBODY)  
POTENTIAL INDICATION: COLORECTAL CANCER

GS-9973 (SYK INHIBITOR)  
POTENTIAL INDICATION: HEMATOLOGICAL MALIGNANCIES

PHASE 1  
GS-5745 (MMP9 MAB INHIBITOR)  
POTENTIAL INDICATION: SOLID TUMORS

## CARDIOVASCULAR DISEASE

PHASE 3  
RANOLAZINE (LATE SODIUM CURRENT INHIBITOR)  
POTENTIAL INDICATION: INCOMPLETE REVASCULARIZATION POST-PCI

RANOLAZINE (LATE SODIUM CURRENT INHIBITOR)  
POTENTIAL INDICATION: TYPE 2 DIABETES

PHASE 2  
RANOLAZINE/DRONEDARONE FIXED-DOSE COMBINATION  
(LATE SODIUM CURRENT INHIBITOR)  
POTENTIAL INDICATION: PAROXYSMAL ATRIAL FIBRILLATION

PHASE 1  
GS-6615 (LATE SODIUM CURRENT INHIBITOR)  
POTENTIAL INDICATION: LONG QT-3 SYNDROME

GS-6615 (LATE SODIUM CURRENT INHIBITOR)  
POTENTIAL INDICATION: HYPERTROPHIC CARDIOMYOPATHY

GS-6615 (LATE SODIUM CURRENT INHIBITOR)  
POTENTIAL INDICATION: VENTRICULAR TACHYCARDIA/VENTRICULAR  
FIBRILLATION

GS-4997 (ASK-1 INHIBITOR)  
POTENTIAL INDICATION: DIABETIC NEPHROPATHY

## RESPIRATORY DISEASE

PHASE 2  
GS-5806 (FUSION INHIBITOR)  
POTENTIAL INDICATION: RESPIRATORY SYNCYTIAL VIRUS

SIMTUZUMAB (MONOCLONAL ANTIBODY)  
POTENTIAL INDICATION: IDIOPATHIC PULMONARY FIBROSIS



# CORPORATE INFORMATION

## BOARD OF DIRECTORS

John C. Martin, PhD  
Chairman and Chief Executive Officer,  
Gilead Sciences

John F. Cogan, PhD  
Lead Independent Director,  
Gilead Sciences  
Senior Fellow, Hoover Institution,  
Stanford University

Etienne F. Davignon  
Minister of State for Belgium,  
Chairman, Genfina

Carla A. Hills  
Chair and Chief Executive Officer,  
Hills & Company, International  
Consultants

Kevin E. Lofton  
President and Chief Executive Officer,  
Catholic Health Initiatives

John W. Madigan  
Retired Chairman and  
Chief Executive Officer,  
Tribune Company

Nicholas G. Moore  
Retired Global Chairman,  
PricewaterhouseCoopers

Richard J. Whitley, MD  
Distinguished Professor,  
Loeb Scholar Chair in Pediatrics,  
Professor of Pediatrics, Microbiology,  
Medicine, and Neurosurgery,  
University of Alabama at Birmingham

Gayle Edlund Wilson  
Immediate Past Chair, Ralph M.  
Parsons Foundation

Per Wold-Olsen  
Retired President, Human Health  
Intercontinental Division,  
Merck & Co., Inc.

DIRECTOR EMERITUS, GILEAD SCIENCES  
BOARD OF DIRECTORS  
George P. Shultz, PhD  
Distinguished Fellow,  
Hoover Institution,  
Stanford University

## SENIOR LEADERSHIP TEAM

John C. Martin, PhD  
Chairman and Chief Executive Officer

John F. Milligan, PhD  
President and Chief Operating Officer

Norbert W. Bischofberger, PhD  
Executive Vice President,  
Research and Development and  
Chief Scientific Officer

Robin L. Washington  
Executive Vice President and  
Chief Financial Officer

Gregg H. Alton  
Executive Vice President,  
Corporate and Medical Affairs

Paul R. Carter  
Executive Vice President,  
Commercial Operations

John McHutchison, MD  
Executive Vice President,  
Clinical Research

Katie L. Watson  
Senior Vice President,  
Human Resources

## SCIENTIFIC ADVISORY BOARD

Joel R. Huff, PhD (Chairperson)  
Retired Vice President of  
Medicinal Chemistry,  
Merck Research Laboratories

Kenneth C. Anderson, MD  
Kraft Family Professor of Medicine,  
Harvard Medical School  
Director, Jerome Lipper Multiple  
Myeloma Center  
Dana-Farber Cancer Institute

Paul Berg, PhD  
Cahill Professor of  
Biochemistry, Emeritus,  
Stanford University School of Medicine

Francis V. Chisari, MD  
Professor of Virology and Immunology,  
The Scripps Research Institute

Brian J. Druker, MD  
Director, Knight Cancer Institute at  
Oregon Health & Science University  
(OHSU), Associate Dean for  
Oncology, OHSU School of Medicine,  
JELD-WEN Chair of Leukemia  
Research, Investigator, Howard  
Hughes Medical Institute

Robert A. Harrington, MD  
Arthur L. Bloomfield Professor of  
Medicine, Chair, Department of  
Medicine, Stanford University  
School of Medicine

Paul E. Klotman, MD  
President and Chief Executive Officer,  
John E. and Clara B. Whitmore  
Professor, Baylor College of Medicine

John W. Mellors, MD  
Professor of Medicine,  
Chief, Division of Infectious Diseases,  
University of Pittsburgh School  
of Medicine

Eugene R. Schiff, MD  
Leonard Miller Professor of Medicine,  
Director for Schiff Liver Institute,  
Director for Center for Liver Diseases,  
University of Miami School of Medicine

Robert T. Schooley, MD  
Professor of Medicine and Head,  
Division of Infectious Diseases,  
Vice Chair of Department of Medicine,  
University of California, San Diego

Eric J. Topol, MD  
Director, Scripps Translational  
Science Institute  
Chief Academic Officer,  
Scripps Health  
Professor of Genomics,  
The Scripps Research Institute

## CORPORATE SECRETARY

Gregg H. Alton  
Executive Vice President, Corporate  
and Medical Affairs

## INDEPENDENT REGISTERED PUBLIC

ACCOUNTANTS  
Ernst & Young LLP  
Palo Alto, California

## CORPORATE HEADQUARTERS

Gilead Sciences, Inc.  
333 Lakeside Drive  
Foster City, CA 94404 USA  
(800) 445-3235 or (650) 574-3000  
www.gilead.com

## STOCKHOLDER INQUIRIES

Inquiries from our stockholders and  
potential investors regarding our  
company are always welcome and  
will receive a prompt response. Please  
direct your requests for information to:

Investor Relations  
Gilead Sciences, Inc.  
333 Lakeside Drive  
Foster City, CA 94404 USA  
(800) 445-3235 or (650) 574-3000

Information regarding Gilead also is  
available at [www.gilead.com](http://www.gilead.com).

## STOCK LISTING

Gilead common stock is traded on the  
Nasdaq Global Select Stock Market,  
under the symbol GILD.

## ANNUAL MEETING

The annual meeting of stockholders  
will be held at 10:00 a.m. on  
Wednesday, May 7, 2014, at the  
Westin San Francisco Airport Hotel.

## TRANSFER AGENT AND REGISTRAR

Communications concerning stock  
transfer requirements, lost certificates  
and changes of address should be  
directed to the Transfer Agent:

Computershare  
P.O. BOX 30170  
College Station, TX 77842-3170  
(800) 710-0940  
www.computershare.com/investor

## EQUAL OPPORTUNITY EMPLOYER

Gilead Sciences is proud to be an  
equal opportunity employer and  
extends employment to men and  
women from culturally diverse  
backgrounds. Our environment  
respects individual differences and  
recognizes each employee as an  
integral member of our company.  
Our workforce reflects these values  
and celebrates the individuals who  
make up our growing team.



Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North and South America, Europe and Asia Pacific.

AmBisome, Cayston, Complera, Emtriva, Eviplera, Gilead, Gilead Sciences, the Gilead logo design, Hepsera, Letairis, Ranexa, Sovaldi, Stribild, Truvada, Tybost, Viread, Vistide, Vitekta and Volibris are registered trademarks of Gilead Sciences, Inc. or one of its related companies. Atripla is a registered trademark of Bristol-Myers Squibb & Gilead Sciences, LLC. Lexiscan is a registered trademark of Astellas U.S. LLC. Tamiflu is a registered trademark of Hoffmann-La Roche Inc. Macugen is a registered trademark of EyeTech, Inc.

Full U.S. prescribing information for Gilead products is available at [www.gilead.com](http://www.gilead.com).



Gilead Sciences, Inc.  
333 Lakeside Drive  
Foster City, California  
94404

650 574 3000 T  
800 445 3235

650 578 9264 F

[www.gilead.com](http://www.gilead.com)